Bobak R. Azamian - 07 Mar 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
President/CEO and Board Chair, Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
07 Mar 2024
Transactions value $
$0
Form type
4
Filing time
11 Mar 2024, 17:57:55 UTC
Previous filing
29 Dec 2023
Next filing
19 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +137K $0.00 137K 07 Mar 2024 Common Stock 137K $35.50 Direct F1
transaction TARS Restricted Stock Units Award $0 +92.5K $0.00 92.5K 07 Mar 2024 Common Stock 92.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service.